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Object:
Several previous studies reported metabolic derangements and an
accumulation of metabolic products in the early phase of experimental subarachnoid
hemorrhage (SAH), which may contribute to secondary brain damage. This may be a
result of deranged oxygen utilization due to enzymatic dysfunction in aerobic glucose
metabolism. This study was performed to investigate, if pyruvate dehydrogenase enzyme
(PDH) is affected in its activity giving further hints for a derangement of oxidative
metabolism.
Methods: Eighteen male Sprague-Dawley rats were randomly assigned to one of two
experimental groups (n = 9): (1) SAH induced by the endovascular filament model and
(2) sham-operated controls. Mean arterial blood pressure (MABP), intracranial pressure
(ICP), and local cerebral blood flow (LCBF; laser-Doppler flowmetry) were continuously
monitored from 30 min before until 3 h after SAH. Thereafter, the animals were sacrificed
and PDH activity was measured by ELISA.
Results: PDH activity was significantly reduced in animals subjected to SAH compared
to controls.
Conclusion: The results of this study demonstrate for the first time a reduction of PDH
activity following SAH, independent of supply of substrates and may be an independent
factor contributing to a derangement of oxidative metabolism, failure of oxygen utilization,
and secondary brain damage.
Keywords: aerobic glycolysis, CBF, metabolism, PDH, SAH, secondary brain damage

INTRODUCTION
Subarachnoid hemorrhage (SAH) is a disease with very poor prognosis. Approximately 15% of
patients die before they are admitted to hospital, the overall mortality is as high as 50%. These
numbers illustrate the significance of secondary brain damage after SAH (van Gijn and Rinkel,
2001). A variety of harmful events like intracerebral hemorrhage, occlusive hydrocephalus, and
a steep increase of ICP and decrease of cerebral perfusion pressure (CPP) cannot be prevented,
because their onset is before hospital admission. However, these events are in the focus of
emergency management when SAH is diagnosed. At the time, the diagnosis is established and
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Laser Doppler Flowmetry and Intracranial
Pressure

treatment has to start, the phase of global perfusion disturbance is
eased already in many patients as ICP has largely recovered after
the initial steep increase (Westermaier et al., 2009a). However,
various mechanisms of secondary brain damage, which have been
reported to arise after SAH or after global brain ischemia, are
potential targets for further therapy (Baethmann et al., 1991;
Siesjö et al., 1995). Extra-/intracellular ion-shifts, an excessive
glutamate release, an early formation of brain edema and
acute vascular and molecular changes have been characterized
as such pathophysiological mechanisms (Sehba and Bederson,
2006). All these mechanisms finally lead to an imbalance of
metabolic demand and oxygen supply. Carpenter et al. showed
by positron emission tomography (PET) in SAH patients on
days 2–5 after aneurysm rupture a significant reduction of the
cerebral metabolic rate of oxygen (CMRO2 ) of 25%, suggesting
primary metabolic alterations and an uncoupling of cerebral
blood flow (CBF) and metabolism after SAH (Carpenter et al.,
1991). Information on metabolism in the first hours after SAH is
rare although this period may be decisive for the final outcome
after aneurysmal SAH since the neurological performance at
the time of first evaluation is one of the best and most reliable
prognostic factors. In previous studies, we found, that despite
incomplete recovery of CBF for more than 6 h after experimental
SAH, tissue oxygenation recovered to baseline level 2 h after SAH
and significantly exceeded this level up to 140% and more of
baseline level after 6 h (Westermaier et al., 2009b). Furthermore,
a persistent increase of lactate and a secondary increasing level of
pyruvate concentration after SAH was monitored (Westermaier
et al., 2011). These observations suggest a persistent failure
of aerobic glycolysis after SAH. The reason for this failure is
unknown to date. The purpose of this study was to investigate,
if the activity of pyruvate dehydrogenase enzyme (PDH)—as a
key enzyme to the TCA cycle—is deranged in the early phase of
experimental SAH.

After induction of anesthesia and oral intubation, a midline
incision of the scalp was performed and two burr holes, 1
mm dorsal and 5 mm lateral of the bregma, were drilled
without injuring the underlying dura mater. For continuous
bilateral monitoring of local cerebral blood flow (LCBF), a
two-channel laser-Doppler flowmeter (MBF3 Laser-Doppler
Flowmeter [LDF], Moor Instruments, Axminster, England) was
used and data was digitally recorded with a frequency of 2 Hz.
For continuous measurement of ICP an additional burr hole
was drilled 3 mm lateral and 0.5 mm anterior of the bregma over
the left frontal cortex.
Thereafter, animals were put in supine position and fixed in
a stereotactic frame. With the help of a micromanipulator, the
rectangularly bent LDF-probes (P5bs, Moor Instruments) were
positioned in each burr hole in the area of the cortex supplied
by the middle cerebral artery (MCA). Also with the help of
a micromanipulator the intraparenchymal ICP probe (Camino,
Integra Neurosciences, Plainsboro, NJ, USA) was inserted with a
depth of 2 mm into the brain.

Induction of SAH
SAH was induced by the endovascular puncture model (Bederson
et al., 1995; Veelken et al., 1995). After a right paramedian
longitudinal incision, the external carotid artery was ligated
and exiting branches were coagulated. Afterwards, temporary
aneurysm clips were put on the common and internal carotid
arteries. The external carotid artery was incised about 6 mm distal
the carotid bifurcation and a 3.0 Prolene filament (Ethicon, Inc.
Somerville, New Jersey) was inserted and secured with a silk
ligature. Then temporary clips were removed, and the external
carotid artery was cut. Thus, the filament could be moved
intracranial via the internal carotid artery. After advancing
approximately 25 mm, a clear descent of ipsilateral CBF was
seen, indicating a correct position of the filament in the internal
carotid artery in front of the exit of the MCA. The filament was
then advanced 3 mm further perforating the vessel in the area
of the anterior cerebral artery (ACA). Immediately thereafter,
the filament was quickly pulled back into the external carotid
artery ascertaining reperfusion of the internal carotid artery. SAH
was verified by a sharp bilateral decrease of LCBF and a sudden
increase of ICP. Continuous measurement of MABP, ICP and
CBF parameters was performed for 3 h after vessel perforation.
After 3 h, the animals were decapitated. Brains were removed,
dissected on a cooling plate and immediately put into fluid
nitrogen (after approximately 60 s) after being stored at −80◦ C
for further experiments.

MATERIALS AND METHODS
For the experiments, 18 male Sprague-Dawley rats (body weight
of 250–300 g) were used, provided by Harlan Winkelmann,
Bochum, Germany. All experiments were approved by the
regional ethics authorities on animal research and the district
government of Bavaria, Germany, and in conformity with the
German Law for animal protection and the National Institute of
Health Guidelines for Care and Use of Laboratory Animals.

Animal Preparation and Monitoring
Induction of anesthesia was performed with 4% isoflurane,
followed by oral intubation and mechanical ventilation with
an air-oxygen mixture to provide normal blood gases. After
induction of anesthesia, isoflurane was lowered to 2.5% for
surgical procedures and to 1.5% from 30 min before induction
of SAH until the end of monitoring period. Temperature
was constantly measured throughout the whole experiment,
maintaining temperatures at 37◦ C. Continuous arterial blood
pressure measurement was performed by cannulating the tail
artery. Blood gas samples were taken 30 and 5 min before SAH,
30 min after SAH and hourly until end of experiment.
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Sample Preparation and Enzyme Linked
Immunosorbant Assay (ELISA)
Brain samples of the right frontal hemisphere were defrosted
and homogenized in phosphate buffered saline (PBS) and protein
concentrations determined by the Bradford method. Protein
concentrations ranged around 27.40 ± 4.18 mg/ml. Thereafter,
PDH activity was measured by the PDH Enzyme Activity
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Microplate Assay Kit (MitoScience, Eugene, Oregon, USA.
ELISA measurement was performed using an ELISA Reader
(Multiskan EX, Labsystems, Finnland). Kinetic measurement was
performed by an optical density (OD) of 450 nm every 10 s up to 3
min with interphase mixing using the kinetic software GENESIS
(Genesis Lite, Version 2.16, Life Sciences, UK).

Experimental Groups
The rats were randomly assigned to one of two groups (n = 9): (1)
SAH induced by the endovascular filament model and (2) sham
operated controls. In the sham group, a 3.0-prolene filament was
also inserted into the external carotid artery, moved further via
the internal carotid artery and was then withdrawn again without
perforating a vessel.

Statistical Analysis
Statistical analysis was performed with GraphPad Prism 4
Statistical Software (GraphPad, San Diego, California, USA).
Physiological data of each point in time as well as ICP and LDF
were analyzed using the unpaired student’s t-test. A P < 0.05
was considered to be significant. Results are presented as mean
± standard deviation.
To test the hypothesized differential development of enzyme
activity between control and SAH animals for statistical
difference we calculated a regression slope for each brain and
compared the slopes by Mann-Whitney U-tests.

FIGURE 1 | Time course of intracranial pressure (ICP) in subarachnoid
hemorrhage (SAH) group and sham-operated group. Measurement from
30 min before until 180 min after induction of SAH. Values are presented as
mean ± standard deviation. *p < 0.05 and **p < 0.01 vs. control group in
each time point.

RESULTS
Physiological Parameters
There were no statistically significant differences between SAH
and sham operated group regarding pH, pO2 , and pCO2 (data
not shown).

Intracranial Pressure (ICP), Mean Arterial
Blood Pressure (MABP) and Cerebral
Perfusion Pressure (CPP)
We did not find a significant elevation of MABP in the present
series (data not shown). The maximum elevation of ICP was 30 ±
14 mmHg 5 min after vessel perforation in animals subjected to
SAH. CPP decreased from a baseline of 58 ± 12 mmHg to a
minimum of 37 ± 18 mmHg and almost completely recovered
after 30 min. The courses of ICP and CPP are depicted in
Figures 1, 2.

FIGURE 2 | Time course of CPP in SAH group and sham-operated
group. Measurement from 30 min before until 180 min after induction of SAH.
Values are presented as mean ± standard deviation. **p < 0.01 vs. control
group in each time point. The initial increase ICP is combined with an
immediate decrease of CPP—significantly reduced in the SAH group until
15 min after SAH.

Local Cortical Blood Flow (LCBF)
In the SAH group, ipsilateral LCBF declined to a minimum of 22
± 12% of baseline 1 min after SAH, recovered to 59 ± 32% after
1 h and picked up further to 66 ± 48% at the end of measurement.
In the control group, ipsilateral LCBF slightly increased to 110 ±
43% of baseline and showed no significant changes throughout
the whole experiment. The decline of ipsilateral LCBF in the SAH
group was significant from induction of SAH until the end of
monitoring period 3 h after SAH (Figure 3 left).
Contralateral LCBF in SAH group declined to a minimum of
40 ± 32% of baseline 5 min after induction of SAH, recovered
to 73 ± 48% after 1 h and further to 98 ± 65% after 3 h at the
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end of experiment. In the sham group, contralateral LCBF slightly
increased to 108 ± 35% of baseline after 1 h and did not show
any significant changes throughout the whole experiment as well.
The decline of contralateral LCBF in SAH group was significant
from induction of SAH until 60 min after SAH (Figure 3
right).
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FIGURE 3 | Time course of local cerebral blood flow (LCBF) ipsilateral (A) and contralateral (B) of vessel perforation/sham operation in SAH group and
sham-operated controls. Measurement from 30 min before until 180 min after induction of SAH. Values are presented as mean ± standard deviation. *p < 0.05,
**p < 0.01, and ***p < 0.001 vs. control group in each time point. The significant decrease of LCBF exceeded the decrease of CPP immediately after SAH until the
end of measurement.

Pyruvate Dehydrogenase Enzyme Activity
PDH activity measured via ELISA and illustrated as optical
density in % of baseline at 450 nm showed a decent trend of
reduction during the whole time course of evaluation. As shown
in Figure 4, PDH activity in SAH animals differed significantly
from PDH activity in control animals (U1 = 410; U2 = 162;
IzI = 123,629 and therefore p < 0.01). There was no significant
correlation between the reduction of PDH activity and the
reduction of CBF in either hemisphere 3 h after induction of
SAH, nor any time-point before.

DISCUSSION
Although the physiological changes in this present series were
rather moderate compared to previous reports using the same
experimental model (Prunell et al., 2004; Westermaier et al.,
2009b, 2011) this study shows a clear depression of PDH activity
in rats subjected to SAH. To our knowledge, there has been
no comparable study reported in literature so far, investigating
the PDH activity in the first hours after SAH in humans nor
in experimental models. The reduced activity of PDH after
SAH, combined with previous findings of elevated glutamate
and lactate levels, secondary and persistent elevation of pyruvate
levels, and a significant increase of the lactate-pyruvate ratio
(LPR) (Westermaier et al., 2009b, 2011) suggest a derangement
of oxidative metabolism in the early phase of SAH. In previous
studies using the same experimental model, we found no signs
of cerebral infarction or hypoxic brain damage (Westermaier
et al., 2009a,b, 2011). Instead, we observed selective damage in
hippocampal neurons. This is in accordance with our finding that
CBF rather quickly recovers to values above ischemic thresholds
as previously defined by various authors (Jones et al., 1981). It
is one limitation of this experimental model that the extent of
SAH and of pathophysiological changes is characterized by a
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FIGURE 4 | Activity of pyruvate dehydrogenase enzyme (PDH)
measured via enzyme linked immunosorbant assay (ELISA) and
illustrated as optical density in % of baseline. PDH activity in SAH
animals differed significantly from PDH activity in control animals (**p < 0.01).

larger variability (Prunell et al., 2004). Thus, mean values of CBF
presented in Figure 3 must be interpreted with caution since they
do not exclude that some animals may have been in a CBF-range
where functional metabolism could already be deranged. The
reduction of PDH activity in SAH animals, however, was highly
consistent and significant suggesting that its reduction after SAH
is not linearly correlated to CBF.
Our observation that the reduction of PDH activity was
independent of the reduction of CBF suggests that there might
be a primary deficiency of the PDH complex in the early stage of
SAH.
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Pyruvate Dehydrogenase Enzyme and
Complex

On the other hand there are studies suggesting that oxidative
stress is probably responsible for the loss of PDH activity,
(Bogaert et al., 1994) as the production of superoxide, hydroxyl
radical, nitric oxide, and peroxynitrite is elevated during
reperfusion (Metodiewa and Koska, 2000). Summarizing these
findings and the results of Liu et al. who found that hyperoxid
resuscitation results in a more pronounced lipid peroxidation
and worse neurological outcome, (Liu et al., 1998) it seems
possible that the PDH is targeted by oxidative stress and that its
inactivation may contribute to neuronal injury and neurologic
impairment.
Lai et al. reported, that Ca2+ inactivates the PDH in vitro (Lai
et al., 1988) and it was therefore concluded that an accumulation
of Ca2+ in mitochondria could be responsible for the inactivation
of PDH and for an imbalanced intracellular homeostasis of
Ca2+ leading to a mitochondrial mediated cell death. However,
Pandaya et al. showed recently a Ca2+ -dependent inhibition of
mitochondrial respiration without influencing PDH and NADH
dehydrogenase (Complex I) (Pandya et al., 2013). With respect
of the complexity of PDH regulation, even a combination of
several mechanisms may be responsible for the reduction of PDH
activity.

Pyruvate dehydrogenase enzyme—located in the outer
mitochondrial matrix—is a key enzyme to the TCA cycle
and oxidative phosphorylation and, therefore, a critical link
between anaerobic and aerobic metabolism (Reed, 1981). Several
studies of PDH function and activity have been conducted in
experimental models of cerebral ischemia and traumatic brain
injury (TBI), but not in SAH so far. Since the pathophysiology
of SAH is different from stroke (a focal ischemia) and post-TBI
(a complex multifocal ischemia) it is to be understood as a
completely different and discrete disease pattern. In contrast
to ischemia (in stroke and TBI), the sudden and distinct
decrease of CBF after SAH is not followed by an appropriate
reperfusion, but recovers slowly and incompletely—rather like
a hypoperfusion persisting for several hours (Westermaier et al.,
2009b).
In experimental rat brain ischemia, Zaidan and Sims (1997)
demonstrated a reduced activity of PDH in the dorsolateral
striatum after 30 min of forebrain ischemia—particularly in
selectively vulnerable neurons. Furthermore, it was shown,
that the reduction of PDH activity in the frontal cortex was
reperfusion-dependent (Bogaert et al., 1994). Because there was
no change of PDH activity in ischemia alone, the authors
suggested that the reduction of PDH activity was a factor of
reperfusion injury.
Regarding reperfusion injury, there might be a difference
compared to SAH. It was shown in this and previous
experimental SAH rat model studies, that CPP decreases
significantly after induction of SAH, but recovers quickly and
is almost restored to normal values after 30 min. LCBF, in turn,
also immediately decreases after induction of SAH, but recovers
much slower and is still markedly reduced after 6 h. LCBF
therefor clearly exceeds the decline of CPP in its duration and
extent. This resembles a kind of a “low flow status” in the early
hours after SAH. The persistent hypoperfusion might lead to
an exceeding and/or longer lasting derangement of oxidative
metabolism, as neurons quickly shift from aerobic to anaerobic
metabolism once the LCBF is lower than 1/3 of normal values
(Siesjo, 1992). This shift from aerobic to anaerobic metabolism
leads to an increase of pyruvate (Westermaier et al., 2011)—
and to changes in the ATP/ADP-ratio, the NADH/NAD+
ratio and the Acetyl-CoA/CoA-ratio (Reed, 1981; Cardell et al.,
1991). That may lead to an imbalance in activity regulation
of PDH via phosphorylation and dephosphorylation, leading to
an activation of pyruvate dehydrogenase kinase and, therefore,
to a decreased activity of PDH by exceeded inhibition. It is
unlikely, that the decrease of PDH in our study was due
to a change in cofactor levels, as the used assay solution
contained sufficient amounts of cofactors (such as pyruvate
and NAD), although the total amounts of pyruvate and NAD
were not measured in this study. Another supplement, that the
decrease in PDH activity is due to the injury and not due to
cofactor limitation is, that the brain samples were put into fluid
nitrogen immediately and therefor NAD, a cofactor of PDH
activity, had no time to degrade spontaneously (Balan et al.,
2010).
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Derangement of Oxidative Metabolism in
(Experimental and Clinical) SAH
Derangement of metabolism and accumulation of metabolites
after SAH have been observed in several studies (Sugi et al.,
1975; Carpenter et al., 1991; Sarrafzadeh et al., 2001, 2005;
Cesarini et al., 2002). MD studies in SAH patients revealed
increased levels of lactate, pyruvate, lactate-pyruvate ratio (LPR),
and glutamate, (Sarrafzadeh et al., 2001, 2005; Cesarini et al.,
2002) measured on several points in time during SAH course.
Information on metabolic changes in the early phase of SAH
is rare, but Westermaier et al. discovered the same pattern
of metabolites in the early phase of SAH in an experimental
rat model, (Westermaier et al., 2011) suggesting a sustained
metabolic depression after SAH. In addition, the incomplete
recovery of CBF which exceeded the decline in ptiO2 seems to
mirror the brain disability of O2 -utilization observed in patient
studies (Carpenter et al., 1991).
The dysfunction of cell metabolism is thought to start the
cascade of ischemic cell death with an early brain edema, lactate
acidosis, and free radicals, leading to a disturbed membrane
potential, which results in an increase of extracellular glutamate
and an influx of intracellular calcium. Cellular and mitochondrial
Ca2+ overload, mitochondrial failure and the increase of
excitatory amino acids are mediators of neuronal cell death.
Finally this turns into a mismatch of supply and demand of
energy. An elevated MD glucose concentration, glutamate, and
LPR have been thought to correlate with poor outcome after SAH
(Persson et al., 1996). The reduced activity of PDH shown in this
study may lead to increased levels of glucose, lactate, pyruvate,
and LPR, giving further support for an impaired aerobic glucose
metabolism following SAH. A direct correlation of reduced PDH
activity and deranged cerebral energy metabolism is still lacking.
Indications for the hypothesis of a direct correlation could be
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histological damage, and clinical outcome after cerebral ischemia
in animals and humans, although the mechanism is still not
fully understood. Dichloroacetate (DCA) was shown to stimulate
PDH activity by inhibition of PDH kinase. The administration
of DCA in animal models of global and focal ischemia led to
a decrease of brain lactate levels and to an improvement of
neurological outcome (Corbett et al., 1998) as well as to a decrease
of brain lactate levels after administration in patients within the
first 2 days after stroke (Graham et al., 2000).
Another target for a potential neuroprotective drug would be
bypassing the PDH reaction and thereby provide “fuel” to the
TCA cycle, which could be possible via ALCAR or ketone-bodies.
Finally, if oxidative stress is responsible for the damage of the
PDH, the treatment of radical formation may improve the PDH
activity and exert a neuroprotective effect by this mechanism.
All these drugs and treatments could be potential preventers of
a PDH dysfunction but—with the exception of antioxidants—
haven’t been tested in the early phase of SAH until now.

the fact, that intravenous administration of acetyl-L-carnitine
(ALCAR) reduced brain lactate levels and improved neurological
outcome, (Rosenthal et al., 1992) probably due to the fact that
the Acetylcarnitine-CoA transferase in brain allows ALCAR to
enter the TCA cycle of neurons and astrocytes (Bresolin et al.,
1982). The loss of PDH activity could lead to secondary brain
damage due to secondary mitochondrial failure—as the failure
of mitochondrial function after SAH has already been observed
by Marzatico (Marzatico et al., 1998). Unfortunately it is not
possible to answer the question, if and to what content the
reduction in PDH activity correlates with cell death and therefore
secondary brain damage following SAH in our study model, as we
euthanized animals 3 h after SAH (to gain information on PDH
activity at this particular and crucial time point of SAH course of
disease) and the earliest time point to detect cell death is 24 h and
would be even better in the following days after SAH. Therefore,
further studies in our group have already been started addressing
this question.
In summary, there might be a shift from aerobic to anaerobic
metabolism already in the early phase after SAH, as we observed
for the first time a reduced activity of PDH combined with a
significant increase of lactate, LPR, and glutamate.

CONCLUSION
For the first time, this study shows a significant reduction of PDH
activity in the early phase of experimental SAH in rats, which
may play part in the derangement of oxidative metabolism found
in previous studies. The inactivation of PDH seems to be an
independent pathophysiological factor, which might contribute
to secondary brain damage after SAH. Further studies will have to
investigate, if PDH is the only affected enzyme or if there is more
damage further “downstream” the aerobic glucose metabolism.

Clinical Implications
Our results indicate that there may be a primary enzymatic
dysfunction of PDH—a key enzyme to the TCA-cycle—after
SAH. Hence, the normalization of CBF in this crucial period
may not be sufficient to prevent secondary brain damage, as the
earliest establishes time-point of treatment of SAH-patients is 3 h
after SAH, which is also the time-point when most patients who
suffered severe SAH reach a hospital and have their diagnosis
of SAH. If aerobic metabolism fails, the brain will eventually
undergo secondary damage, typically selective neuronal damage
as has repeatedly been found in this experimental model.
It cannot be concluded from this data how big the impact
of this metabolic derangement on brain damage is and how
its long-term course is. However, there could be a potential
target for a future neuroprotective treatment of SAH patients
already in the early phase after SAH, immediately after hospital
admission. Our data indicates also that the inactivation of
PDH represents an independent pathophysiological factor, which
might contribute to secondary brain damage after SAH. The
protection against PDH inactivation as well as compensation
for metabolic disruption could exert protective efficacy and
act as a neuroprotective factor. Ca2+ -channel blockers were
found to have a beneficial effect on metabolic parameters,
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